Nurix to present updated Phase 1 NX-5948 data at investor meetings starting Sept 5

Nurix Therapeutics, Inc.

Company began investor roadshow on September 5, 2024, with an updated investor slide deck.
Deck includes new data from the Phase 1 trial of NX-5948 for various B-cell malignancies.
No specific numerical results (e.g., response rates, safety) are disclosed in this 8-K filing.
NX-5948 is a targeted protein degrader; the full presentation may contain efficacy/safety details.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.